TW200411179A - HTS-capable method and assay system for determining the interaction between C-reactive protein and components binding to C-reactive protein - Google Patents

HTS-capable method and assay system for determining the interaction between C-reactive protein and components binding to C-reactive protein Download PDF

Info

Publication number: TW200411179A
Authority: TW; Taiwan
Prior art keywords: group; component; components; donor; crp
Prior art date: 2002-06-12

Application number

TW092115617A

Other languages

English (en)

Chinese (zh)

Inventor

Aimo Kannt

Antje Pommereau

Original Assignee

Aventis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-12

Filing date

2003-06-10

Publication date

2004-07-01

2003-06-10 Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh

2004-07-01 Publication of TW200411179A publication Critical patent/TW200411179A/zh

Links

238000000034 method Methods 0.000 title claims abstract description 69
238000009739 binding Methods 0.000 title claims abstract description 44
230000027455 binding Effects 0.000 title claims abstract description 30
230000003993 interaction Effects 0.000 title claims abstract description 15
108010074051 C-Reactive Protein Proteins 0.000 title abstract description 78
102100032752 C-reactive protein Human genes 0.000 title abstract description 78
238000003556 assay Methods 0.000 title abstract 2
239000000126 substance Substances 0.000 claims abstract description 27
150000001875 compounds Chemical class 0.000 claims description 67
108020003175 receptors Proteins 0.000 claims description 41
238000004458 analytical method Methods 0.000 claims description 15
238000013537 high throughput screening Methods 0.000 claims description 15
239000002245 particle Substances 0.000 claims description 14
238000012360 testing method Methods 0.000 claims description 14
230000002079 cooperative effect Effects 0.000 claims description 12
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
230000005540 biological transmission Effects 0.000 claims description 9
210000002966 serum Anatomy 0.000 claims description 9
238000001514 detection method Methods 0.000 claims description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
230000004913 activation Effects 0.000 claims description 6
239000000872 buffer Substances 0.000 claims description 6
239000004615 ingredient Substances 0.000 claims description 6
230000033228 biological regulation Effects 0.000 claims description 5
210000002381 plasma Anatomy 0.000 claims description 5
230000000694 effects Effects 0.000 claims description 4
229920001184 polypeptide Polymers 0.000 claims description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 4
102000004196 processed proteins & peptides Human genes 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 3
230000002285 radioactive effect Effects 0.000 claims description 3
206010061218 Inflammation Diseases 0.000 claims description 2
230000003213 activating effect Effects 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
210000000056 organ Anatomy 0.000 claims description 2
STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims 1
208000006011 Stroke Diseases 0.000 claims 1
229940125878 compound 36 Drugs 0.000 claims 1
230000005284 excitation Effects 0.000 claims 1
239000002002 slurry Substances 0.000 claims 1
239000000243 solution Substances 0.000 description 17
239000004005 microsphere Substances 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
230000024203 complement activation Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
238000012216 screening Methods 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
230000005855 radiation Effects 0.000 description 3
239000011535 reaction buffer Substances 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000013642 negative control Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
150000003248 quinolines Chemical class 0.000 description 2
239000000376 reactant Substances 0.000 description 2
235000015170 shellfish Nutrition 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
108090001008 Avidin Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
241000283707 Capra Species 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
101000958041 Homo sapiens Musculin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229910052778 Plutonium Inorganic materials 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000003016 alphascreen Methods 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000002309 gasification Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
102000046949 human MSC Human genes 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000009004 jinqing Substances 0.000 description 1
239000002523 lectin Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
OYEHPCDNVJXUIW-UHFFFAOYSA-N plutonium atom Chemical compound [Pu] OYEHPCDNVJXUIW-UHFFFAOYSA-N 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
238000007781 pre-processing Methods 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
229940071559 trioxin Drugs 0.000 description 1
238000009834 vaporization Methods 0.000 description 1
230000008016 vaporization Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Food Science & Technology (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)

TW092115617A 2002-06-12 2003-06-10 HTS-capable method and assay system for determining the interaction between C-reactive protein and components binding to C-reactive protein TW200411179A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10226011A DE10226011A1 (de)	2002-06-12	2002-06-12	HTS-fähiges Verfahren und Testsystem zur Ermittlung der Wechselwirkung zwischen c-reaktivem Protein und an C-reaktives Protein bindenden Komponenten

Publications (1)

Publication Number	Publication Date
TW200411179A true TW200411179A (en)	2004-07-01

Family

ID=29718976

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW092115617A TW200411179A (en)	2002-06-12	2003-06-10	HTS-capable method and assay system for determining the interaction between C-reactive protein and components binding to C-reactive protein

Country Status (14)

Country	Link
EP (1)	EP1516187A2 (de)
JP (1)	JP2005529348A (de)
CN (1)	CN1745300A (de)
AR (1)	AR040259A1 (de)
AU (1)	AU2003250344A1 (de)
BR (1)	BR0311709A (de)
CA (1)	CA2489021A1 (de)
DE (1)	DE10226011A1 (de)
MX (1)	MXPA04012232A (de)
NO (1)	NO20050037L (de)
RU (1)	RU2005100042A (de)
TW (1)	TW200411179A (de)
WO (1)	WO2003107000A2 (de)
ZA (1)	ZA200409199B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102721813A (zh) *	2012-07-09	2012-10-10	沃克(天津)生物科技有限公司	前列腺特异抗原均相发光免疫分析检测试剂盒及其检测方法
CN103852465A (zh) *	2012-11-30	2014-06-11	通用电气公司	检测标记蛋白的方法和装置
AU2016341539A1 (en) *	2015-10-02	2018-04-26	Tgr Biosciences Pty Ltd.	Analyte detection with multiple substrates
CN107976535B (zh) *	2017-11-03	2020-03-20	科美诊断技术股份有限公司	一种检测样本中目标IgM抗体的均相免疫检测试剂盒及其使用方法和应用
CN109752332A (zh) *	2017-11-07	2019-05-14	重庆中元汇吉生物技术有限公司	一种补体C1q检测试剂盒
CN108169497A (zh) *	2018-02-11	2018-06-15	北京科美生物技术有限公司	人泌乳素检测试剂盒及其制备方法与应用
CN108445239B (zh) *	2018-02-11	2021-11-02	科美诊断技术股份有限公司	检测β人绒毛膜促性腺激素的均相免疫检测试剂套装及其制备方法和应用
CN108490194A (zh) *	2018-02-11	2018-09-04	北京科美生物技术有限公司	检测卵泡刺激素的均相免疫检测试剂套装及其制备方法和应用
CN108445238A (zh) *	2018-02-11	2018-08-24	北京科美生物技术有限公司	检测促黄体生成素的均相免疫检测试剂套装及其制备方法和应用
CN108445216B (zh) *	2018-02-11	2021-10-15	科美诊断技术股份有限公司	一种人抗缪勒氏管激素测定试剂盒及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0411017B1 (de) *	1988-04-04	1996-03-06	POTEMPA, Lawrence A.	Bindung von immunkomplexen durch modifizierte formen von c-reaktiven proteinen
US6140490A (en) *	1996-02-01	2000-10-31	Nexstar Pharmaceuticals, Inc.	High affinity nucleic acid ligands of complement system proteins
US5283238A (en) *	1992-04-24	1994-02-01	Immtech International, Inc.	Methods of treating cancer using modified C-reactive protein
JP3498960B2 (ja) *	1993-09-03	2004-02-23	デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング	蛍光酸素チャンネリングイムノアッセイ
US6303325B1 (en) *	1998-05-29	2001-10-16	Dade Behring Inc.	Method for detecting analytes

2002
- 2002-06-12 DE DE10226011A patent/DE10226011A1/de not_active Withdrawn
2003
- 2003-06-10 BR BR0311709-0A patent/BR0311709A/pt not_active IP Right Cessation
- 2003-06-10 MX MXPA04012232A patent/MXPA04012232A/es not_active Application Discontinuation
- 2003-06-10 CA CA002489021A patent/CA2489021A1/en not_active Abandoned
- 2003-06-10 EP EP03759923A patent/EP1516187A2/de not_active Withdrawn
- 2003-06-10 CN CNA03813442XA patent/CN1745300A/zh active Pending
- 2003-06-10 TW TW092115617A patent/TW200411179A/zh unknown
- 2003-06-10 AR ARP030102067A patent/AR040259A1/es unknown
- 2003-06-10 WO PCT/EP2003/006038 patent/WO2003107000A2/de not_active Ceased
- 2003-06-10 RU RU2005100042/15A patent/RU2005100042A/ru not_active Application Discontinuation
- 2003-06-10 JP JP2004513768A patent/JP2005529348A/ja active Pending
- 2003-06-10 AU AU2003250344A patent/AU2003250344A1/en not_active Abandoned
2004
- 2004-11-17 ZA ZA200409199A patent/ZA200409199B/en unknown
2005
- 2005-01-04 NO NO20050037A patent/NO20050037L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
JP2005529348A (ja)	2005-09-29
WO2003107000A3 (de)	2004-05-27
WO2003107000A2 (de)	2003-12-24
AU2003250344A1 (en)	2003-12-31
BR0311709A (pt)	2005-03-15
AR040259A1 (es)	2005-03-23
RU2005100042A (ru)	2006-07-20
NO20050037L (no)	2005-01-04
DE10226011A1 (de)	2004-01-08
CN1745300A (zh)	2006-03-08
ZA200409199B (en)	2005-05-18
MXPA04012232A (es)	2005-02-25
EP1516187A2 (de)	2005-03-23
CA2489021A1 (en)	2003-12-24

Publication	Publication Date	Title
ES2340667T3 (es)	2010-06-08	Inmunodeficiencia homogeneos para multiples alergenos.
US4234563A (en)	1980-11-18	Insolubilized deoxyribonucleic acid (DNA)
US5225328A (en)	1993-07-06	Stable alkaline phosphatase compositions with color enhancement and their use in assays
TW200411179A (en)	2004-07-01	HTS-capable method and assay system for determining the interaction between C-reactive protein and components binding to C-reactive protein
CN116203251A (zh)	2023-06-02	一种用于检测磷酸化Tau蛋白的试剂盒
CN107589249B (zh)	2020-04-07	用于通过免疫复合物转移法检测被检物质的抗体试剂及其制造方法、以及该抗体试剂的用途
US3914400A (en)	1975-10-21	Stable antigen-erythrocytes for measuring antibodies against toxoplasma organism
JPH03251764A (ja)	1991-11-11	緩衝化洗浄組成物および試験キットならびに使用方法
CN104749355B (zh)	2017-02-01	一种磺胺类的检测方法及其检测试剂盒
US4251514A (en)	1981-02-17	Insolubilized deoxyribonucleic acid (DNA)
CN102980884A (zh)	2013-03-20	胃黏膜样品中幽门螺旋杆菌的化学发光免疫测定法
EP0556745A1 (de)	1993-08-25	Verfahren zum Nachweis von Anti-Weizenprotein-Antikörpern
WO2000052469A1 (en)	2000-09-08	Method for assaying crp with the use of phosphorylcholine
US20030232394A1 (en)	2003-12-18	High throughput screening method and assay system for determining the interaction between C-reactive protein and components binding to it
US4254097A (en)	1981-03-03	Method of detecting antibodies to human thyroglobulin
Stipic et al.	2015	Application of functionalized lanthanide-based nanoparticles for the detection of okadaic acid-specific immunoglobulin G
WO2022136576A1 (en)	2022-06-30	Liposome-receptor-assay for detecting neutralizing antibodies
JP4437003B2 (ja)	2010-03-24	Ｅｖｈ１ドメインまたはｅｖｈ１ドメインを有するタンパク質とｅｖｈ１結合ドメインまたはｅｖｈ１結合ドメインを有するタンパク質との相互作用を調節する化合物をスクリーニングする方法およびその相互作用を検出する方法
JP2532651B2 (ja)	1996-09-11	抗核抗体測定用器具の製法
EP0601131A1 (de)	1994-06-15	Bindung von milchallergenen an eine festphase
Zhang et al.	2018	Preparation and evaluation of combined detection of norovirus GI and GII: An innovative fluorescent particles test strip
JP4068259B2 (ja)	2008-03-26	免疫測定方法及び乾式免疫測定試薬
KR20050020985A (ko)	2005-03-04	Ｃ-반응성 단백질과 ｃ-반응성 단백질에 결합하는 성분간의 상호작용의 측정
CN120761647A (zh)	2025-10-10	一种抗可提取核抗原抗体测定试剂盒配制方法
JP2025006951A (ja)	2025-01-17	ハプテンの測定方法